Document is current
Any future updates will be listed below
-
Authors
Martin, Samantha https://orcid.org/0009-0009-8673-7583
Elomaa, Hanna
Väyrynen, Juha P. https://orcid.org/0000-0002-8683-2996
Ahtiainen, Maarit
Wirta, Erkki-Ville https://orcid.org/0000-0002-2255-6136
Böhm, Jan
Seppälä, Toni T.
Ristimäki, Ari
Tahkola, Kyösti
Mattila, Anne
Koskensalo, Selja
Renkonen-Sinisalo, Laura
Lepistö, Anna
Mecklin, Jukka-Pekka
Palin, Kimmo https://orcid.org/0000-0002-4621-6128
Rajamäki, Kristiina
Aaltonen, Lauri A. https://orcid.org/0000-0001-6839-4286
- License Information
-
More Information
Article History
Received: 17 April 2025
Revised: 25 November 2025
Accepted: 3 December 2025
First Online: 14 January 2026
Competing interests
: TTS reports consultation fees from Amgen, Tillots Pharma, Orion Pharma, Nouscom and Mehiläinen, and a position in the Clinical Advisory Board and a minor shareholder of Lynsight Ltd.
: This study has been conducted in accordance with the Declaration of Helsinki and has been approved by the ethics committee of the hospital district of Helsinki and Uusimaa. All samples included in this research were derived after informed consent.
